The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma

• Published in: Leukemia & lymphoma 2016-12, Vol.57 (12), p.2763-2770
• Main Authors: Tomita, Naoto, Suzuki, Taisei, Miyashita, Kazuho, Yamamoto, Wataru, Motohashi, Kenji, Tachibana, Takayoshi, Takasaki, Hirotaka, Kawasaki, Rika, Hagihara, Maki, Hashimoto, Chizuko, Takemura, Sachiya, Koharazawa, Hideyuki, Yamazaki, Etsuko, Taguchi, Jun, Fujimaki, Katsumichi, Fujita, Hiroyuki, Sakai, Rika, Fujisawa, Shin, Motomura, Shigeki, Kawamoto, Keisuke, Sone, Hirohito, Takizawa, Jun
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived - adverse effects; Antibodies, Monoclonal, Murine-Derived - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; Cyclophosphamide - adverse effects; Cyclophosphamide - therapeutic use; Diffuse large B-cell lymphoma; Doxorubicin - adverse effects; Doxorubicin - therapeutic use; Female; Humans; Lactate Dehydrogenases - blood; Lymphoma, Large B-Cell, Diffuse - blood; Lymphoma, Large B-Cell, Diffuse - diagnosis; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - mortality; Male; Middle Aged; Neoplasm Staging; Prednisone - adverse effects; Prednisone - therapeutic use; Prognosis; R-CHOP; Receptors, Interleukin-2 - blood; SIL index; soluble interleukin-2 receptor; Survival Analysis; Treatment Outcome; Vincristine - adverse effects; Vincristine - therapeutic use; Young Adult
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428194.2016.1195498

We previously developed a prognostic index, SIL, which includes advanced stage (S), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP). This time we evaluated the index in a larger cohort and its utility in the risk stratification. The above three factors were independent risk of progression-free survival (PFS). Five-year PFS rates in the standard-risk (SIL index: 0 or 1, n = 367) and high-risk groups (SIL index: 2 or 3, n = 205) were 79% and 53%, respectively (p 60 years), the SIL index was a good prognostic indicator for PFS in both groups as well as divided by the number of extranodal involvement site (0-1 and >1). The SIL index is a simple and objective prognostic indicator in DLBCL.